Figure 2.
Time line of treatment approvals in B-ALL. Brexu-cel, brexucabtagene autoleucel; Car, chimeric antigen receptor; MRD, measurable residual disease; Ph-neg, Philadelphia negative; R/R, relapsed/refractory; Tisa-cel, tisagenlecleucel.

Time line of treatment approvals in B-ALL. Brexu-cel, brexucabtagene autoleucel; Car, chimeric antigen receptor; MRD, measurable residual disease; Ph-neg, Philadelphia negative; R/R, relapsed/refractory; Tisa-cel, tisagenlecleucel.

Close Modal

or Create an Account

Close Modal
Close Modal